Repositioning Candidate Details
| Candidate ID: | R0589 |
| Source ID: | DB03604 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Tiratricol |
| Synonyms: | 3',3,5-Triiodothyroacetic acid; Tiratricol; Triiodothyroacetic acid |
| Molecular Formula: | C14H9I3O4 |
| SMILES: | OC(=O)CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1 |
| Structure: |
|
| DrugBank Description: | A metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome. |
| CAS Number: | 51-24-1 |
| Molecular Weight: | 621.9323 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Thyroid hormone receptor beta |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I06 | 811 | Lipodystrophy | A connective tissue disease that is characterized by marked reduction, absence, and/or the redistribution of adipose tissue. https://www.ncbi.nlm.nih.gov/pubmed/25690482, https://www.ncbi.nlm.nih.gov/pubmed/25833179 | disease of anatomical entity/ musculoskeletal system disease/ connective tissue disease | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |